Epigenetic & microRNA Regulation Analysis Service for Cell Cycle Program
Creative Biolabs moves projects from genomic observation to functional regulatory insight by decoding the "Epi-miRNA" axis. We identify how histone marks or DNA methylation control miRNA expression, especially during G1/S or G2/M transitions governed by tumor-suppressive miRNA silencing. Our service identifies "pharmacologically unmaskable" targets—miRNAs silenced in disease but reactivatable via small molecules. This dual-layer analysis ensures therapeutic candidates are grounded in robust regulatory logic and actionable mechanisms.
Background Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Introduction to the Epi-miRNA Cell Cycle Axis
The interaction between microRNAs and epigenetic machinery forms a critical regulatory circuit. While DNA methylation and histone modifications control miRNA transcription, "epi-miRNAs" simultaneously target epigenetic modifiers like DNMTs and HDACs. In cell cycle regulation, clusters such as miR-130b/301b act as molecular switches; their loss through CpG island hypermethylation often overactivates drivers like MET and CDK4. Creative Biolabs utilizes high-resolution ChIP-Seq to identify marks like H3K27me3, pinpointing clusters for pharmacological reactivation. This integrated analysis effectively identifies high-confidence therapeutic targets to "unmask" pathways and restore cell cycle checkpoints in malignant cells.
Ready to uncover hidden therapeutic targets? Request a Specialist Consultation to Discuss Your Project Goals
High-Resolution Analytical Workflow
Creative Biolabs delivers an integrated ecosystem of technologies designed to capture the dynamic interplay between the epigenome and the small RNA transcriptome.
Publication
This review explores the intricate epigenetic regulation of microRNAs (miRNAs) in cancer, emphasizing the bidirectional relationship between DNA methylation, histone modifications, and miRNA expression. It details how miRNA dysregulation contributes to tumorigenesis and examines their potential as diagnostic and prognostic biomarker. The article also highlights emerging therapeutic strategies targeting these epigenetic mechanisms, underscoring the clinical relevance of miRNAs in advancing cancer management from basic research to clinical applications.
Fig.1 The biogenesis process of microRNAs.1
Why Choose Us?
Creative Biolabs stands as an industry leader in regulatory genomics by offering a unique platform, a specialized pipeline optimized for capturing the full diversity of the small RNA transcriptome. While standard services often overlook low-abundance miRNAs and subtle isomiR variations, our platform provides the sensitivity required for clinical-grade biomarker discovery. We prioritize a synchronized analytical approach, mapping "upstream" epigenetic drivers and "downstream" miRNA targets within a single batch to eliminate the technical noise associated with cross-platform data merging. Our PhD-led bioinformatic team doesn't simply deliver data; we provide functional interpretations of feedback loops, identifying actionable targets for precision medicine. With a proven track record in "pharmacological unmasking" strategies, we help you transform genomic complexity into a streamlined drug development roadmap.
Leverage our expertise for your next breakthrough — Experience the Creative Biolabs Advantage and Get a Detailed Quote
FAQs
How do you handle low-input samples?
Creative Biolabs offers specialized low-input protocols optimized for biopsies or rare cell populations, ensuring reliable data from limited starting materials.
Can you distinguish between different isomiRs?
Yes, the platform provides single-nucleotide resolution to identify subtle isomiR variations and low-copy-number miRNAs with high fidelity.
What is the advantage of combined ChIP-Seq and RNA-Seq?
Combining these allows us to confirm whether a decrease in miRNA expression is due to epigenetic silencing (repressive histone marks) or other post-transcriptional factors.
Customer Review
-
Unparalleled Precision
Using Creative Biolabs' integrated pipeline in our cell cycle research significantly facilitated the identification of the miR-193a-3p/E2F regulatory axis. The resolution of the H3K27me3 mapping was exceptional. - Dr. Al** S
-
Comprehensive Insights
The exosomal miRNA analysis service helped us overcome low-yield challenges from samples. It provided the clarity needed for our biomarker validation. - Prof. Ma** K
Related Services
Single-Cell Cell-Cycle State & Lineage Dynamic Inference
Creative Biolabs transforms transcriptomic snapshots into predictive models, distinguishing cell-cycle fluctuations from differentiation. We resolve temporal continuums to identify progenitor states and mechanistic targets.
Learn More →
Inflammatory Reaction Detection Service
Creative Biolabs provides cardiotoxicity and inflammation testing. We identify biomarkers and analyze signaling pathways to predict drug-induced cardiac dysfunction during early screening.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs provides a world-class service that bridges the gap between genomic data and therapeutic breakthroughs. By integrating epigenetic mapping with deep miRNA profiling, we empower researchers to decode complex disease mechanisms and accelerate the development of next-generation precision medicines.
For detailed project discussions or to receive a tailored proposal, please reach out to our scientific team.
Reference
-
Pajares, María J., et al. "Epigenetic regulation of microRNAs in cancer: shortening the distance from bench to bedside." International Journal of Molecular Sciences 22.14 (2021): 7350. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms22147350
For Research Use Only | Not For Clinical Use
Download our brochure